The detection of plasma levels of connective tissue growth factor in rheumatoid arthritis patients

Clinical and Experimental Rheumatology

Volumn 30, Issue 1, 2012, Pages 145-146

  Fujishiro, M ^a   Ogawa, H ^a   Yamaguchi, A ^a,b   Endo, K ^c   Kawasaki, M ^a   Ng, P S ^c   Nozawa, K ^a,b   Takehara, K ^d   Takasaki, Y ^b   Sekigawa, I ^a,e   Takamori, K ^a  

^a JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Nihon Nosan Corporation   (Japan)

^d KANAZAWA UNIVERSITY   (Japan)

^e JUNTENDO UNIVERSITY URAYASU HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CONNECTIVE TISSUE GROWTH FACTOR; INFLIXIMAB; STROMELYSIN;

AMINO TERMINAL SEQUENCE; BLOOD ANALYSIS; BLOOD SAMPLING; DISEASE ASSOCIATION; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; LETTER; LEUKOCYTE COUNT; OSTEOCLAST ACTIVITY; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN DETERMINATION; PROTEIN FUNCTION; RHEUMATOID ARTHRITIS;

ADULT; AGED; ARTHRITIS, RHEUMATOID; CONNECTIVE TISSUE GROWTH FACTOR; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 84863731110     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Letter

References (9)

1. GROTENDORST GR. Connective tissue growth factor: a mediator of TGF-beta action on fibroblasts. Cytokine Growth Factor Rev 1997; 8: 171-9.
2. TAKIGAWA M, NAKANISHI T, KUBOTA S, NISHIDA T. Role of CTGF/HCS24/ecogenin in skeletal growth control. J Cell Physiol 2003; 194: 256-66.
3. PERBAL B. CCN proteins: multifunctional signalling regulators. Lancet 2004; 363: 62-4.
4. SEKIGAWA I, YANAGIDA M, IWABUCHI K et al. Protein biomarker analysis by mass spectrometry in patients with rheumatoid arthritis receiving antitumor necrosis factor-alpha antibody therapy. Clin Exp Rheumatol 2008; 26: 261-7.
5. NOZAWA K, FUJISHIRO M, KAWASAKI M et al. Connective tissue growth factor promotes articular damage by increased osteoclastogenesis in patients with rheumatoid arthritis. Arthritis Res Ther 2009; 11: R174.
6. MIYAZAKI O, KURASHITA S, FUKAMACHI I, ENDO K, NG PS, TAKEHARA K. Subtraction method for determination of N-terminal connective tissue growth factor. Ann Clin Biochem 2010; 47: 205-11.
7. KAWASHIRI SY, KAWAKAMI A, UEKI Y et al. Decrement of serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis (RA) patients achieving remission after 6 months of etanercept treatment: comparison with CRP, IgM-RF, MMP-3 and anti-CCP Ab. Joint Bone Spine 2010; 77: 418-20.
8. UNTERGASSER G, GANDER R, LILG C, LEPPERDINGER G, PLAS E, BERGER P. Profiling molecular targets of TGF-beta 1 in prostate fibroblast-tomyofibroblast transdifferentiation. Mech Ageing Dev 2005; 126: 59-69.
9. SMOLEN JS, HAN C, BALA M et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 2005; 52: 1020-30.